U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H28F4N4O4
Molecular Weight 572.5506
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LETERMOVIR

SMILES

COC1=CC=CC(=C1)N2CCN(CC2)C3=NC4=C(F)C=CC=C4[C@H](CC(O)=O)N3C5=CC(=CC=C5OC)C(F)(F)F

InChI

InChIKey=FWYSMLBETOMXAG-QHCPKHFHSA-N
InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C29H28F4N4O4
Molecular Weight 572.5506
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Letermovir (AIC246 or MK-8228), a 3,4-dihydro-quinazoline- 4-yl-acetic acid derivative, is the prototype viral terminase complex inhibitor that is most advanced in its clinical development. The novel compound was initially developed by AiCuris. In April 2011, the drug was granted orphan drug designation for prevention of CMV disease by the European Commission. In August 2011, the US Food and Drug Administration granted it a fast track designation. In 2012, the results of Phase IIb clinical trials using letermovir in bone marrow transplant patients were presented at various international meetings, and the data were subsequently published in 2014.42 It`s continued clinical development is currently undertaken in agreement with Merck. Letermovir is highly potent in vitro and in vivo against cytomegalovirus. Because of a distinct mechanism of action, it does not exhibit cross-resistance with other antiviral drugs. It is predicted to be active against strains that are resistant to ganciclovir, foscarnet, and cidofovir. To date, early-phase clinical trials suggest a very low incidence of adverse effects. It targets the UL56 subunit of the viral terminase complex. Letermovir is currently in Phase III development.

Originator

Approval Year

TargetsConditions
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 14 weeks after transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
Route of Administration: oral or intravenous
In Vitro Use Guide
Letermovir revealed potent antiviral activity against 17 HCMV clinical isolates, with 50% effective concentrations (EC50s) in the low nanomolar range (0.8-3.1nM).
Substance Class Chemical
Created
by admin
on Tue Mar 06 10:56:20 UTC 2018
Edited
by admin
on Tue Mar 06 10:56:20 UTC 2018
Record UNII
1H09Y5WO1F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LETERMOVIR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
AIC246
Code English
LETERMOVIR [WHO-DD]
Common Name English
(4S)-2-(8-FLUORO-2-(4-(3-METHOXYPHENYL)PIPERAZIN-1-YL)-3-(2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL)-3,4-DIHYDROQUINAZOLIN-4-YL)ACETIC ACID
Systematic Name English
4-QUINAZOLINEACETIC ACID, 8-FLUORO-3,4-DIHYDRO-2-(4-(3-METHOXYPHENYL)-1-PIPERAZINYL)-3-(2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL)-, (4S)-
Common Name English
MK-8228
Code English
2-((4S)-8-FLUORO-2-(4-(3-METHOXYPHENYL)PIPERAZIN-1-YL)-3-(2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL)-4H-QUINAZOLIN-4-YL)ACETIC ACID
Systematic Name English
AIC-246
Code English
LETERMOVIR [JAN]
Common Name English
LETERMOVIR [INN]
Common Name English
AIC 246
Code English
LETERMOVIR [USAN]
Common Name English
PREVYMIS
Brand Name English
Code System Code Type Description
EPA CompTox
917389-32-3
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
WIKIPEDIA
LETERMOVIR
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
CAS
917389-32-3
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
ChEMBL
CHEMBL1241951
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
EVMPD
SUB90389
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
EU-Orphan Drug
EU/3/11/849(POSITIVE)
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY On 15 April 2011, orphan designation (EU/3/11/849) was granted by the European Commission to AiCuris GmbH & Co. KG, Germany, for (S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3, 4-dihydro-4-quinazolinyl} acetic acid for the prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at risk. The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in March 2013.
PUBCHEM
45138674
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY SWITZERF
INN
9384
Created by admin on Tue Mar 06 10:56:20 UTC 2018 , Edited by admin on Tue Mar 06 10:56:20 UTC 2018
PRIMARY
Related Record Type Details
ACTIVE MOIETY